Home World News FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma World News FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 429 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Indications for Serplulimab April 22, 2026 Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... May 5, 2020 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... August 29, 2022 Latest episode of our podcast for cancer researchers March 23, 2022 Load more HOT NEWS FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive,... Coping With Life After a Bone Marrow Transplant: A Survivor’s Story Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later...
